TopoTarget, G2M Cancer Drugs AG deal

TopoTarget acquired G2M for an undisclosed sum. G2M's PEAC (Pulse Enhanced Acetylation) formulation of the HDAC inhibitor G2M-777 is expected to start Phase II testing in 2005 to treat colon cancer. Its Baceca, a topical formulation of the same molecule, is in Phase II testing to treat patients with an inflammatory skin disease and will begin Phase II in skin cancer this year. G2M also has its Zemab antibody-based compound, which has completed Phase I trials in cancer. ...